Peregrine Pharmaceuticals Announces Public Offering of Series E Preferred Stock

Peregrine Pharmaceuticals Receives FDA Fast Track Designation for Its Immunotherapy Bavituximab as a Potential Treatment of Second-Line Non-Small Cell Lung Cancer

Peregrine Pharmaceuticals Initiates Sunrise Pivotal Phase III Clinical Trial of Bavituximab in Second-Line Non-Small Cell Lung Cancer

Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2014 Financial Results and Recent Developments

Peregrine Pharmaceuticals Announces Upcoming Events

Data Presentation at Society for Immunotherapy of Cancer Annual Meeting Supports Potential of Peregrine Pharmaceuticals' Novel Immunotherapy Bavituximab in Combination With Anti-CTLA-4 Antibodies

Peregrine Pharmaceuticals to Present at Credit Suisse 2013 Healthcare Conference

Symposium at IASLC World Conference on Lung Cancer to Highlight Novel Immune Checkpoints Including Peregrine Pharmaceuticals' Bavituximab PS Target

Peregrine Pharmaceuticals Reports First Quarter Fiscal Year 2014 Financial Results and Recent Developments

Data Supporting Bavituximab's Immunotherapy Mechanism of Action Published in the Peer-Reviewed AACR Journal Cancer Immunology Research